000062028 001__ 62028 000062028 005__ 20200221144349.0 000062028 0247_ $$2doi$$a10.1515/cclm-2015-0821 000062028 0248_ $$2sideral$$a95040 000062028 037__ $$aART-2016-95040 000062028 041__ $$aeng 000062028 100__ $$aSanchis-Gomar, F. 000062028 245__ $$aGalectin-3, osteopontin and successful aging 000062028 260__ $$c2016 000062028 5060_ $$aAccess copy available to the general public$$fUnrestricted 000062028 5203_ $$aBackground: Individuals who reach exceptional longevity (100+ years of age) free of common chronic age diseases (i.e. ''dodgers'') arguably represent the paradigm of successful aging in humans. As such, identification of potential biomarkers associated with this phenomenon is of medical interest. Methods: We measured serum levels of galectin-3 and osteopontin, both of which have been shown to be linked with major chronic or aging-related disorders in younger populations, in centenarian ''dodgers'' (n=81; 40 men; 100-104 years) and healthy controls (n=41; 24 men, 70-80 years). Results: Both biomarkers showed significantly lower values (p<0.001) in the former (galectin-3: 2.4±1.7 vs. 4.8±2.8 ng/mL; osteopontin: 38.1±27.7 vs. 72.6±33.1 µg/mL). Logistic regression analysis identified the combination of these two biomarkers as a significant predictor variable associated with successful aging regardless of sex (p<0.001). The area under the curve (AUC) classified the ability of galectin-3 and osteopontin to predict the likelihood of successful aging as ''fair'' (AUC=0.75) and ''good'' (AUC=0.80), respectively. Particularly, the combination of the two biomarkers showed good discriminatory power for successful aging (AUC=0.86), with sensitivity=83% and specificity=74%. Conclusions: Lower levels of both galectin-3 and osteopontin are associated with successful aging, representing potential biomarkers of this condition. Our cross-sectional data must be however approached with caution. Further research is necessary to replicate the present preliminary results in other cohorts and to identify the potential use of galectin-3 and osteopontin as potential targets (or at least predictors) in future personalized anti-aging therapies. 000062028 540__ $$9info:eu-repo/semantics/openAccess$$aAll rights reserved$$uhttp://www.europeana.eu/rights/rr-f/ 000062028 590__ $$a3.432$$b2016 000062028 591__ $$aMEDICAL LABORATORY TECHNOLOGY$$b5 / 30 = 0.167$$c2016$$dQ1$$eT1 000062028 592__ $$a1.038$$b2016 000062028 593__ $$aBiochemistry (medical)$$c2016$$dQ1 000062028 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1 000062028 593__ $$aClinical Biochemistry$$c2016$$dQ2 000062028 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000062028 700__ $$aSantos-Lozano, A. 000062028 700__ $$aPareja-Galeano, H. 000062028 700__ $$0(orcid)0000-0001-8374-9081$$aGaratachea, N.$$uUniversidad de Zaragoza 000062028 700__ $$aAlis, R. 000062028 700__ $$aFiuza-Luces, C. 000062028 700__ $$aMorán, M. 000062028 700__ $$aEmanuele, E. 000062028 700__ $$aLucia, A. 000062028 7102_ $$11006$$2245$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Educación Física y Depor. 000062028 773__ $$g54, 5 (2016), 873-877$$pClin. chem. lab. med.$$tClinical Chemistry and Laboratory Medicine$$x1434-6621 000062028 8564_ $$s692214$$uhttps://zaguan.unizar.es/record/62028/files/texto_completo.pdf$$yVersión publicada 000062028 8564_ $$s127498$$uhttps://zaguan.unizar.es/record/62028/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000062028 909CO $$ooai:zaguan.unizar.es:62028$$particulos$$pdriver 000062028 951__ $$a2020-02-21-13:54:10 000062028 980__ $$aARTICLE